A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).

Clicks: 428
ID: 102890
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #2 of 15 articles by views in the new zealand medical journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.
Reference Key
talreja2020athe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Talreja, Hari;Tan, Jasmine;Dawes, Matt;Supershad, Sharen;Rabindranath, Kannaiyan;Fisher, James;Valappil, Sajed;van der Merwe, Veronica;Wong, Lisa;van der Merwe, Walter;Paton, Julian;
Journal the new zealand medical journal
Year 2020
DOI
DOI not found
URL URL not found
Keywords
coronavirus public policy pandemic

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.